Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Evidence that the catenane form of CS2 hydrolase is not an artefact.

van Eldijk MB, van Leeuwen I, Mikhailov VA, Neijenhuis L, Harhangi HR, van Hest JC, Jetten MS, Op den Camp HJ, Robinson CV, Mecinović J.

Chem Commun (Camb). 2013 Sep 14;49(71):7770-2. doi: 10.1039/c3cc43219j.

PMID:
23771150
2.

Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2.

van Leeuwen IM, Higgins M, Campbell J, McCarthy AR, Sachweh MC, Navarro AM, Laín S.

Mol Cancer Ther. 2013 Apr;12(4):471-80. doi: 10.1158/1535-7163.MCT-12-0904.

3.

Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner.

McCarthy AR, Sachweh MC, Higgins M, Campbell J, Drummond CJ, van Leeuwen IM, Pirrie L, Ladds MJ, Westwood NJ, Laín S.

Mol Cancer Ther. 2013 Apr;12(4):352-60. doi: 10.1158/1535-7163.MCT-12-0900.

4.

Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).

Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, Gauthier-Villars M, Lasset C, Fricker JP, Peock S, Frost D, Evans DG, Eeles RA, Paterson J, Manders P, van Asperen CJ, Ausems MG, Meijers-Heijboer H, Thierry-Chef I, Hauptmann M, Goldgar D, Rookus MA, van Leeuwen FE; GENEPSO.; EMBRACE.; HEBON..

BMJ. 2012 Sep 6;345:e5660. doi: 10.1136/bmj.e5660.

5.

Cyclotherapy: opening a therapeutic window in cancer treatment.

van Leeuwen IM.

Oncotarget. 2012 Jun;3(6):596-600.

6.

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.

van Leeuwen IM, Rao B, Sachweh MC, Laín S.

Cell Cycle. 2012 May 1;11(9):1851-61. doi: 10.4161/cc.20254.

7.

Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers.

Pijpe A, Mulder RL, Manders P; HEBON., van Leeuwen FE, Rookus MA.

J Clin Epidemiol. 2011 Dec;64(12):1434-43. doi: 10.1016/j.jclinepi.2011.04.005.

PMID:
21764559
8.
9.

Mechanism-specific signatures for small-molecule p53 activators.

van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L, Westwood NJ, Laín S.

Cell Cycle. 2011 May 15;10(10):1590-8.

PMID:
21490429
10.

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S.

Oncotarget. 2010 Nov;1(7):639-50.

11.

Dynamic energy budget approaches for modelling organismal ageing.

van Leeuwen IM, Vera J, Wolkenhauer O.

Philos Trans R Soc Lond B Biol Sci. 2010 Nov 12;365(1557):3443-54. doi: 10.1098/rstb.2010.0071. Review.

12.

Body weight and risk of breast cancer in BRCA1/2 mutation carriers.

Manders P, Pijpe A, Hooning MJ, Kluijt I, Vasen HF, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer H, Ausems MG, van Os TA, Gomez-Garcia EB, Brohet RM; HEBON., van Leeuwen FE, Rookus MA.

Breast Cancer Res Treat. 2011 Feb;126(1):193-202. doi: 10.1007/s10549-010-1120-8.

PMID:
20730487
13.

Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers.

Pijpe A, Manders P, Mulder RL, van Leeuwen FE, Rookus MA; Hereditary Breast and Ovarian Cancer Study, the Netherlands..

Eur J Epidemiol. 2010 Feb;25(2):103-13. doi: 10.1007/s10654-009-9416-x.

PMID:
20066476
14.

Systems biologists seek fuller integration of systems biology approaches in new cancer research programs.

Wolkenhauer O, Auffray C, Baltrusch S, Blüthgen N, Byrne H, Cascante M, Ciliberto A, Dale T, Drasdo D, Fell D, Ferrell JE Jr, Gallahan D, Gatenby R, Günther U, Harms BD, Herzel H, Junghanss C, Kunz M, van Leeuwen I, Lenormand P, Levi F, Linnebacher M, Lowengrub J, Maini PK, Malik A, Rateitschak K, Sansom O, Schäfer R, Schürrle K, Sers C, Schnell S, Shibata D, Tyson J, Vera J, White M, Zhivotovsky B, Jaster R.

Cancer Res. 2010 Jan 1;70(1):12-3. doi: 10.1158/0008-5472.CAN-09-2676.

15.

An integrative computational model for intestinal tissue renewal.

van Leeuwen IM, Mirams GR, Walter A, Fletcher A, Murray P, Osborne J, Varma S, Young SJ, Cooper J, Doyle B, Pitt-Francis J, Momtahan L, Pathmanathan P, Whiteley JP, Chapman SJ, Gavaghan DJ, Jensen OE, King JR, Maini PK, Waters SL, Byrne HM.

Cell Prolif. 2009 Oct;42(5):617-36. doi: 10.1111/j.1365-2184.2009.00627.x.

PMID:
19622103
16.

Sirtuins and p53.

van Leeuwen I, Lain S.

Adv Cancer Res. 2009;102:171-95. doi: 10.1016/S0065-230X(09)02005-3. Review.

PMID:
19595309
17.

SysBioMed report: advancing systems biology for medical applications.

Wolkenhauer O, Fell D, De Meyts P, Blüthgen N, Herzel H, Le Novère N, Höfer T, Schürrle K, van Leeuwen I.

IET Syst Biol. 2009 May;3(3):131-6. doi: 10.1049/iet-syb.2009.0005.

PMID:
19449974
18.

Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.

de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ, Vasen HF, ter Huurne JA, Frants RR, Willemze R, Breuning MH, Gruis NA.

Clin Cancer Res. 2008 Nov 1;14(21):7151-7. doi: 10.1158/1078-0432.CCR-08-0403.

19.

Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families.

de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W, van der Drift C, van Leeuwen I, van Mourik L, Huurne JA, Frants RR, Willemze R, Breuning MH, Trent JM, Gruis NA.

Eur J Hum Genet. 2008 Sep;16(9):1135-41. doi: 10.1038/ejhg.2008.72.

20.

Towards a multiscale model of colorectal cancer.

van Leeuwen IM, Edwards CM, Ilyas M, Byrne HM.

World J Gastroenterol. 2007 Mar 7;13(9):1399-407. Review.

Items per page

Supplemental Content

Loading ...
Support Center